BROSSARD, QUEBEC–(Marketwired – May 20, 2016) – DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, is pleased to announce, effective immediately, the appointment of Mr. Tristam Coffin and Mr. Jean-Yves Thérien as directors of the Corporation.
Mr. Coffin is highly respected in the eye care field, with a weld of experience. Mr. Coffin is the owner of one of Canada’s most prestigious optical centres in Montreal. “I am excited to take an active role in developing the strategy and continued growth in sales derived from the Corporation’s innovative proprietary software platform to assist eye specialists in the detection of diabetic retinopathy,” said Mr. Coffin.
Mr. Jean-Yves Thérien currently serves as Vice President of Business Development for Nippon Dragon Resources Inc., a TSX venture exchange company in the exploration and development stage and previous to that he served as a financial advisor at Laurentian Bank for over 13 years. Mr. Thérien has a Bachelor in business administration with a specialization in finance.
These appointments follow the resignation of Mr. Michael Singer, effective immediately, and Mr. Lloyd M. Segal, effective June 1st, 2016. Lloyd will end his nearly two-year tenure with DIAGNOS after working with the company to develop its go-to-market strategy, expanding the global reach of DIAGNOS’ CARA product, and working with management to develop a plan to ensure the sustainable growth of the company. He noted that, “DIAGNOS is well-positioned, with the right technology, for the early-diagnosis and treatment of diabetic retinopathy patients across the globe.” “I take this opportunity to thank Michael and Lloyd for their dedication and service to DIAGNOS shareholders,” said Mr. André Larente, President of Diagnos. Mr. Philip Renaud will assume the role of chairman of the board.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission to improve the quality of patients’ lives and minimize the economic burden of vision loss. Computer Assisted Retinal Analysis (CARA) is the Company’s proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, the U.S. Food and Drug Administration, and the European Union.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Andre Larente
President
1-877-678-8882 or (450) 678-8882, ext.: 224
